Ohara Pharmaceutical is focused on developing innovative treatments, particularly in the areas of orphan drugs and generic pharmaceuticals. The company emphasizes its commitment to addressing rare medical conditions through the development of specialized medications, such as Glucarpidase (Megludase®) and Unituxin®, which are designed to treat specific health issues like methotrexate intoxication and childhood cancers. Their approach to drug development is rooted in genetic recombination techniques, allowing for the creation of targeted therapies that can significantly improve patient outcomes.

In addition to its work in orphan drugs, Ohara Pharmaceutical is also involved in expanding healthcare infrastructure, particularly in sub-Saharan Africa, through partnerships aimed at enhancing dialysis services. This initiative reflects the company's broader mission to provide dependable pharmaceuticals and improve healthcare access in underserved regions. By focusing on both innovative drug development and global health initiatives, Ohara Pharmaceutical aims to contribute positively to the future of medicine and patient care.

Japan

 At Ohara, we are aiming to provide not only treatment options for patients, but also aiming to identify and develop innovative tools to improve the quality of diagnosis, prevention and after care in an effort to become a Total Healthcare Solution company for patients.

Ohara Pharmaceutical

Company Details